Evidence map›Paper›PMID 29265902›Full record

ReviewPlatelets2018

Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug.

Annachiara Mitrugno, Joanna L Sylman, Rachel A Rigg, Samuel Tassi Yunga, Joseph J Shatzel, Craig D Williams, Owen J T McCarty

Open access · greenAbstract readReview
In one paragraph

Review in Platelets, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. The role of coagulation and platelets in colon cancer-associated thrombosis.American journal of physiology. Cell physiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Annachiara Mitrugnoa Department of Biomedical Engineering , Oregon Health & Science University, Portland, OR, USA.
Joanna L Sylmana Department of Biomedical Engineering , Oregon Health & Science University, Portland, OR, USA.
Rachel A Rigga Department of Biomedical Engineering , Oregon Health & Science University, Portland, OR, USA.
Samuel Tassi Yungad Cancer Early Detection & Advanced Research Center , Oregon Health & Science University, Portland, OR, USA.
Joseph J Shatzelc Division of Hematology & Medical Oncology , Oregon Health & Science University, Portland, OR, USA.
Craig D Williamsh School of Pharmacy , Oregon State University , Portland , OR , USA.
Owen J T McCartya Department of Biomedical Engineering , Oregon Health & Science University, Portland, OR, USA.
Oregon Health & Science University · USOregon State University · US

Funding

Characterization of Coagulation Factor-platelet Interactions: Role of FXIR01HL101972 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Owen J McCarty · 2010 to 2026
$8.5M
FXI and SepsisR01GM116184 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2015 to 2018
$1.9M
NHLBI NIH HHS R01 HL101972NIGMS NIH HHS R01 GM116184
6 · The paper itself

Abstract

Cancer metastasis is a dynamic process during which cancer cells separate from a primary tumor, migrate through the vessel wall into the bloodstream, and extravasate at distant sites to form secondary colonies. During this process, circulating tumor cells are subjected to shear stress forces from blood flow, and in contact with plasma proteins and blood cells of the immune and hemostatic system, including platelets. Many studies have shown an association between high platelet count and cancer metastasis, suggesting that platelets may play an occult role in tumorigenesis. This mini-review summarizes recent and emerging discoveries of mechanisms by which cancer cells activate platelets and the role of activated platelets in promoting tumor growth and metastasis. Moreover, the review discusses how aspirin has the potential for being clinically used as an adjuvant in cancer therapy.

Indexed as

NeoplasmsAnimalsAntineoplastic AgentsAspirinHumansNeoplasm MetastasisPlatelet ActivationPlatelet Aggregation InhibitorsPlatelet CountAntineoplastic AgentsAspirinPlatelet Aggregation InhibitorsAspirinCancerPlatelets

Identifiers

PMID29265902
PMCPMC6185807
OpenAlexW2780018177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.